PharmaFocus Today – Page 63 – media

Vice President Wang Maochun paid a working visit to the China Center for Assistive Devices for Persons with Disabilities

On the morning of August 9, Vice President Wang Maochun and his delegation paid a working visit to the China Center for Assistive Devices for Persons with Disabilities, and had pragmatic exchanges with Kong Deming, Secretary of the Party Branch and Director of the Center, on the development of the assistive device industry and the participation of Chinese assistive device companies in international cooperation. The Chamber of Commerce’s External Cooperation Department and Exhibition Department accompanied the meeting. Vice President Maochun briefly introduced the basic situation of the Medical Insurance Chamber of Commerce in helping domestic pharmaceutical companies to develop internationally over the years, and highly appreciated the contributions of the Assistive Devices Center in promoting the distribution of assistive device products and improving the level of technological research and development innovation. He said that the Medical Insurance Chamber of Commerce is willing to work with the Assistive Devices Center to ...
- Source: drugdu
- 87
- September 1, 2024
Tonghua Jinma Oral Drug Succinium Octahydroaminoacridine Tablets Listing Application Accepted

On the evening of August 29, Tonghua Jinma announced that the company recently received the State Drug Administration issued a listing application for succinium octahydroaminoacridine tablets “Notice of Acceptance”, the oral drug for light, moderate Alzheimer’s disease (Alzheimer’s disease, AD) treatment. On the same day, Tonghua Jinma plate rushed to a halt, closing up 9.98%, closing price of 14.54 yuan / share. Alzheimer’s disease as one of the most common neurodegenerative diseases, the number of its patients with the aging trend of the population and rising. According to the introduction, Succinum Octahydroaminoacridine Tablets is a new, potent, clear mechanism of action of cholinesterase inhibitors, is a new chemical 1 class of drugs with complete independent intellectual property rights, new chemical molecular structure, domestic and foreign have not been marketed. The results of the main pharmacodynamic study show that the drug exhibits strong inhibition of both acetylcholinesterase and butyrylcholinesterase, and by ...
- Source: drugdu
- 76
- September 1, 2024
Analysis and Prospect of Import and Export Situation of Raw Materials in the First Half of 2024

In the first half of 2024, the total import and export volume of raw materials in China reached 26.52 billion US dollars, a year-on-year increase of 0.6%. Among them, the export value was 21.34 billion US dollars, a slight increase of 0.1% year-on-year; The import volume was 5.18 billion US dollars, a year-on-year increase of 2.8%. 1. Overall Overview and Trend Analysis As the main raw material products in the category of Western medicine import and export products in China, active pharmaceutical ingredients account for 50% of Western medicine foreign trade. From the perspective of exports alone, raw materials account for 80% of the export of Western medicine products. From the import and export situation since 2021, it can be seen that the global demand for active pharmaceutical ingredients has rapidly increased due to the epidemic. In 2022, the foreign trade of active pharmaceutical ingredients reached a historical high, with ...
- Source: drugdu
- 101
- August 31, 2024
Fulbright Medicalwithdraws its application for issuance and listing

On August 23rd, the IPO review status of Jiangsu Fulbright Medical Equipment Co., Ltd. (referred to as Fulbright Medical) on the Science and Technology Innovation Board of the Shanghai Stock Exchange changed to “terminated”. Due to the withdrawal of the issuance and listing application by Fulbright Medical and its sponsor, in accordance with Article 63 of the Shanghai Stock Exchange’s Stock Issuance and Listing Review Rules, the Shanghai Stock Exchange has terminated its issuance and listing review. The Shanghai Stock Exchange issued an inquiry letter on July 23, 2023 regarding the review of the application documents for the initial public offering and listing of Jiangsu Fulbright Medical Equipment Co., Ltd. on the Science and Technology Innovation Board, requiring Fulbright Medical to respond to multiple questions regarding its main products, market, volume based procurement, core technology, and more. On January 17, 2024, Fulbright Medical updated its response to the first round ...
- Source: drugdu
- 94
- August 31, 2024
Chongqing’s first Class 1 innovative biological drug is launched

On August 27, Chongqing’s first Class 1 biological innovative drug, Celici monoclonal antibody injection, was approved for marketing, achieving a “zero” breakthrough in Chongqing’s biological product innovative drug track. According to Zhixiang Jintai’s official microblog, Celici monoclonal antibody injection is its first product approved for marketing and the first fully human IL-17A target drug in China. Indications for the birth of the “king of medicine” Moderate to severe plaque psoriasis as an indication is regarded as the “Gold Coast” in the field of autoimmune indications. The former “king of medicine” Humira was born from it. Due to the complexity of the psoriasis pathway itself, there are also many antigens that can be targeted in the pathway. The more typical one is the previous generation of “king of medicine” Humira. Adalimumab is a monoclonal antibody targeting TNF-α. This target has a wide range of adaptability for autoimmune diseases. Its indications range ...
- Source: drugdu
- 80
- August 31, 2024
Treatment of small cell lung cancer enters a period of accelerated breakthroughs

In the field of tumors, any breakthrough is not easy. Although humans have discovered cancer for a long time, chemotherapy has long been the core treatment method. Of course, after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. For example, after decades of silence, the treatment of small cell carcinoma seems to have ushered in a period of accelerated breakthroughs. On August 15, AstraZeneca announced that its drug durvalumab has been accepted by the FDA for the indication of limited small cell lung cancer (LS-SCLC). If approved for marketing, this will be the first immunotherapy in 40 years to show survival benefits in this field, representing an important breakthrough. For limited-stage SCLC, the current first-line treatment is still chemoradiotherapy, especially the treatment of cisplatin combined with etoposide, which occupies an absolute dominant position in treatment. Amgen has also made progress in the field ...
- Source: drugdu
- 122
- August 31, 2024
Internet healthcare is more than just selling drugs

Can the business model of Internet healthcare work without selling drugs? This may be the answer that everyone wants to know at the moment. After all, Internet healthcare is recognized as a tough nut to crack. Many entrants have fallen halfway, and some survivors are not in a good situation. Ping An Health’s latest semi-annual report finally gave a definite answer. In the first half of the year, Ping An Health’s adjusted net profit reached 89.74 million yuan, a year-on-year loss of 340 million yuan. This achievement was not easy to come by. Ten years after its establishment, Ping An Health finally achieved its first profit; if compared with JD Health and Ali Health, Ping An Health’s turnaround time is also later, but the latter’s turnaround may be more meaningful to the entire Internet healthcare. The core is that, in the eyes of the outside world, whether it is JD ...
- Source: drugdu
- 81
- August 31, 2024
Part of the Product Market Promotion Did Not Meet Expectations

Relying on the agency products, “vaccine quality leading stock” Zhifei Biological delivered a double-digit revenue and net profit in the first half of the results, bluntly said that part of the region, part of the product marketing work did not meet expectations. The evening of August 29, Chongqing Zhifei Biological Products Co., Ltd (Zhifei Biological, 300122) announced 2024 semi-annual report, operating income of 18.258 billion yuan, a year-on-year decline of 25.31%; the mother of the net profit of 2.234 billion yuan, a year-on-year decline of 47.55%; the mother of the deduction of non-net profit of 2.23 billion yuan, a year-on-year decline of 47.04%. Zhifei biological performance decline is not a surprise. This year’s quarterly report shows that its quarterly operating income of 11.396 billion yuan, up 2% year-on-year; mother net profit of 1.458 billion yuan, down 28.26% year-on-year; mother deducted net profit of 1.455 billion yuan, down 28.36% year-on-year. Combined ...
- Source: drugdu
- 83
- August 31, 2024
After being acquired by Mindray Medical, Huitai Medical’s annual report still shows high growth

Recently, Huitai Medical released its latest semi annual report, with a total revenue of 1 billion yuan in the first half of 2024, a year-on-year increase of 27.03%; Net profit of 343 million yuan, an increase of 33.09%; The non net profit attributable to the parent company was 328 million yuan, an increase of 35.2%. This is the first semi annual report of Huitai Medical after being acquired by Mindray Medical, and it still maintains a high growth trend. The combination of competitive advantages and cost-effectiveness brought by strong cooperation, and being in an important window of domestic substitution, can Huitai Medical achieve rapid development without speed limit from now on? Strong collaboration Being able to be acquired by the industry leader itself indicates that Huitai Medical is excellent enough. On January 29th, Mindray Medical announced that it had acquired a total of 14.1203 million shares of Huitai Medical held ...
- Source: drugdu
- 162
- August 30, 2024
Siemens Healthineers plans to acquire Novartis’ diagnostic business for €200 million

Recently, according to the Financial Times, Siemens Healthineers plans to acquire the diagnostic business of Advanced Accelerator Applications (AAA), a subsidiary of Novartis, for 200 million euros (approximately 1.593 billion yuan). AAA specializes in producing radioactive nuclide drugs, also known as nuclear drugs, for molecular imaging equipment PET (positron emission tomography). The transaction is expected to be completed in the fourth quarter. Expand business territory AAA was spun off from the European Organization for Nuclear Research (CERN) in 2002 and is an innovative radiopharmaceutical company focused on targeted radioligand therapy, precise radioligand imaging, and molecular imaging product development. Its main focus is on the development, production, and commercial application of Molecular Nuclear Medicine (MNM) products. On October 30, 2017, Novartis acquired the company for $3.9 billion to strengthen its radiopharmaceutical business capabilities, making AAA a subsidiary of Novartis. After years of development, AAA has built a pipeline covering various diagnostic ...
- Source: drugdu
- 108
- August 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.